- -- Quick Links --
- The focus
- Industry Speak
- BioAsia 2012
- BioAsia 2011
- BioAsia 2010
- BioAsia 2009
- Proceedings 2012
- Proceedings 2011
- Proceedings 2010
- Proceedings 2009
- Photo Gallery 2012
- Photo Gallery 2011
- Photo Gallery 2010
- Photo Gallery 2009
- Video Gallery 2012
- Video Gallery 2011
- Contact Us
Dr. Seth Berkley
As a physician, epidemiologist and leading advocate for vaccines and immunisation, Dr Seth Berkley brings many years of experience and knowledge from the fields of public health, development and vaccines to the work of the Alliance. Seth joined the GAVI Alliance in August 2011 as it launched its five year strategy to immunise a quarter of a billion children in the developing world with life-saving vaccines by 2015.
Dr. Urmish Chudgar
Dr. Urmish Chudgar is the Managing Director of Intas Biopharmaceuticals Limited, an biopharmaceutical entity of Intas group. Intas Group derives its competitive edge from successful and strategic moves it has made in the areas of Manufacturing, R&D, Biotechnology, Clinical Research and Global Operations.
Mr. Kevin Ali
Kevin Ali holds the position of President, Emerging Markets with responsibility for leading Merck's overall emerging markets strategy and is a member of GHHOC. Kevin most recently held the position of Senior Vice President and General Manager, BRID Franchise, Global Human Heath Marketing in Whitehouse Station, NJ at Merck & Co., Inc. Corporate Headquarters.
Dr. Anand Tharmaratnam
Dr. Anand Tharmaratnam is Senior Vice President and Head of Asia Markets, Clinical Development for Quintiles. In this role, Dr. Tharmaratnam has responsibility for the Quintiles clinical development business across the Asia-Pacific region, including Japan. In the Asia-Pacific region alone, Quintiles has more than 25 offices and employs approximately 3,800 full-time clinical development professionals.
Dr. Richard D. Connell
Rick is based in Shanghai, China to help establish the Anti-infective (AI) Research unit. He previously headed up the External Research Solutions Center of Emphasis (ERS COE) that managed the network of pre-clinical contract research organizations supporting Pfizer Research.
Dr. Harry S. Rathore
Dr. Harry S. Rathore is the Managing Director and head of Lonza India Operations. Lonza India Private Limited is a leading supplier to the pharmaceutical, healthcare and life science industries headquartered in Basel, Switzerland. It is life sciences driven company and leading custom manufacturer of active ingredients, intermediates, APIs and biopharmaceuticals.
Prof. Nirmal Kumar Ganguly
Prof. Nirmal Kumar Ganguly is a Distinguished Biotechnology Research Professor at the National Institute of Immunology, New Delhi. He is also President of the Jawaharlal Institute of Post Graduate Medical Education and Research, Pondicherry. He is former Director General of the Indian Council of Medical Research.
Dr. Darren Ji
Dr. Darren Ji is the CEO and founder of PharmaLegacy Laboratories, a leading preclinical pharmacology CRO (contract research organization) based in Shanghai. PharmaLegacy has been a preferred service provider in the area of disease models to many of the top biopharmaceutical companies worldwide. Previously, Darren was the Director of Bioscience Business Development – East Asia for the Procter & Gamble Company.
Dr. Suresh Jadhav
Dr. S. S. Jadhav, M.Pharm. Ph.D. from Nagpur University started his career in 1970 with research fellowship of CSIR. He held a decade of academic career at the Dept. of Pharmaceutical Sciences, Nagpur; S.N.D.T. University/ Mumbai and Haffkine Institute, Mumbai. Dr. Jadhav joined Serum Institute of India Ltd., Pune in 1979, and holds the position of Executive Director since 1992.
Dr. Cyrus Karkaria
Cyrus Karkaria is currently President of the Biotechnology division of Lupin Pharma is based in Pune. Prior to that he was Vice President at Celldex Therapeutics and CuraGen Corporation in New Haven, Connecticut, USA heading Operations and Biopharmaceutical Process Sciences. He has also held positions at Biogen Idec and Scios. He has been part of teams that have developed multibillion $ blockbusters in the field of neurology immunology and oncology such as Avonex, Amevive and Tysabri (Biogen Idec) from the bench to manufacturing scale (2000L to 15,000L).
Dr. Hasit Joshipura
Dr. Hasit Joshipura is a graduate in Electrical Engineering from VJTI - Bombay University and a Post Graduate from Indian Institute of Management - Ahmedabad. He has completed his Doctorate programme at the School of Management at IIT Mumbai.
Dr. P. V. Appaji
Dr. P. V. Appaji, a doctorate in Pharmaceutical Sciences from Nagpur started his career in 1975 with the Drugs Control Organization, Government of Andhra Pradesh. Currently working as Executive Director/CEO of Pharmaceuticals Export Promotion Council (PHARMEXCIL) at Hyderabad, Dr. Appaji has contributed significantly to the development of pharmaceutical industry in India.
Mr. K V Balasubramaniam
Mr. K V Balasubramaniam, Managing Director, Indian Immunologicals Ltd. holds a graduate degree in Mechanical Engineering from the Madras University (1979), Masters degree in Management from the Indian Institute of Management, Ahmedabad (1981) and a PG Diploma in Patents Law from Nalsar University of Law (2008).
Mr. Swapan Bhattacharya
Swapan Bhattacharya is the Managing Director of TCG Lifesciences Limited (formerly "Chembiotek Research International"), a leading life sciences research services and Informatics Company in India and part of The Chatterjee Group (TCG), a global investment conglomerate headquartered in New York.
Dr. Wenyong Wang
Wenyong Wang is currently a Managing Director, Merchant and Investing Banking at Burrill & Company. Dr. Wang has more than 18 years experience in the healthcare industry. Prior to joining Burrill Merchant Banking, Dr. Wang was a senior executive member of Boenning & Scattergood Global Healthcare Investment Banking practice, where he initiated and led Merger & Acquisition, licensing & partnering, capital raising, fairness opinions, as well as other financial and scientific advisory activities in public and private life sciences companies. He had managed over 25 public offerings and private placements, as well as M&A assignments ranging from $5 million to $500 million, in an aggregated value of over two billion dollars.
Dr Sumit Ghoshal
Dr. Ghoshal is a healthcare writer with 25 years of full time experience in mainstream newspapers and magazines in Mumbai, mostly with the Indian Express. From May 2006 till the present time, he has been working in a senior position with Business India magazine, writing extensively on pharmaceuticals, healthcare delivery, biotechnology and life sciences.
Mr. Narayanan Suresh
Narayanan Suresh is the Group Editor( Senior VP) of BioSpectrum, India's first biotechnology magazine, published by CyberMedia simultaneously from India and Singapore. In fact, BioSpectrum is the first ever Indian magazine title to be published from outside India for a global audience.
Mr. Harish Iyer
Harish has extensive experience in the biotechnology industry and was previously Vice-President and Head of Research & Development, Biocon (2001-2011). With a team of 300+ top scientists, Harish worked on numerous projects at Biocon including recombinant human insulin & analogues, BioMAb EGFR antibody and novel discovery projects such as oral insulin and other first-in-class biologics in the Biocon R&D pipeline.
Dr. Sandeep Gupta
Dr. Sandeep Gupta is the Senior Vice President of Drug Discovery and Early Development at Endo Pharmaceuticals Inc. based in Chadds Ford, PA. At Endo, Dr. Gupta oversees all aspects of research and development activities in oncology, pain, urology and endocrinology therapeutic areas from discovery stage to Phase 1. He has devised and implemented a semi-virtual drug discovery model and established a number of successful collaborations in India and Europe.
Mr. Rajesh Rai
Rajesh Rai is CEO of India Innovation Fund. He currently serves on the Boards of Mitra Biotech, Surewaves and Sedemac. Rajesh brings over 15 years of industry experience including over 9 years of venture investing experience to his position. Rajesh co-founded and served as Partner with New Markets Venture Partners (NMVP), a leading venture capital fund in the Washington DC region with over 20 portfolio companies in information technology, health care and education.
Mr. Vishal Gandhi
Vishal Gandhi is Senior Vice President & Head –Life Sciences at YES BANK. He leads the Life Sciences Knowledge Banking initiative for YES BANK working as the key stakeholder responsible for Origination, Advisory & Execution Oversight of Corporate Banking / Investment Banking deals in the sector.
Dr. Shirshendu Mukherjee
Dr. Shirshendu Mukherjee,. Worked with reputed Pharmaceuticals and diagnostic companies in India like Ranbaxy , JK Drugs and Pharmaceuticals and Becton Dicknson his main area of research, was development of diagnostics,bioprocesses for biopharmaceuticals and vaccines.
Dr. Shoibal Mukherjee
Dr. Shoibal Mukherjee is Chief Medical Officer at Quintiles India, based in Delhi NCR. In this role he represents Quintiles' position on a wide variety of government, ethical and public policy issues. He also guides and works very closely with the Quintiles clinical business team.
Dr. Prabuddha K Kundu
Prabuddha has studied from IIT-Bombay. His specialization is primarily in the protein expression and scale up of biomolecules and MAbs. He has over 16 years of experience in various companies, and positions, including establishment of production facilities, for biologicals, vaccines and blood derived products. He has worked for companies such as Bio-Rad, Ranbaxy, etc.
Dr. Goutam Das
Ph.D. in Biology with post doctoral training in the USA. Started career with Astra Research Centre India Bangalore (ARCI was a wholly owned subsidiary of Astra AB, Sweden, currently AstraZeneca Plc) as a senior scientist in 1988.
Dr. Sunny Sharma
Dr. Sunny Sharma is a Senior Managing Director on the Asia team of OrbiMed Advisors. Dr. Sharma has more than a dozen years of life sciences experience spanning venture capital, investment banking, and clinical practice. Dr. Sharma was previously with Investor Growth Capital (IGC), the wholly
Dr. Sanjay Mittal
Dr. Mittal received his medical training from L.L.R.M Medical College, Meerut. Thereafter, he completed his DM in Cardiology from Lucknow in 1994.
Mr. Sai D. Prasad
Sai Prasad has 20 years of progressive experience in the United States and India in Biological sciences, Strategic planning, Project management, Business Development etc. He has expertise in basic science research (molecular biology, cell biology, human genetics, cell culture), good laboratory practices good manufacturing practices etc.
Mr. Kewal Handa
Kewal Handa has been Managing Director of Pfizer Limited, India since 2005. Prior to this, Kewal served as Executive Director - Finance, Pfizer Limited. Kewal is also Managing Director of Wyeth Ltd.
Mr. Atul Aslekar
Atul is a co-founder of VLife Sciences Technologies Pvt Ltd. He brings over 18 years experience in technology development in large international organizations like Fujitsu and Indian companies like Zensar. He was also associated as a strategic consultant with companies like Siemens AG and Mahindra & Mahindra Ltd.
Mr. Utkarsh Palnitkar
Senior Life Sciences professional with in-depth experience across the life sciences spectrum. Set up and led the Life Sciences practice for Ernst & Young, India. 25 + years experience. Harvard Business School, Chartered Accountant. Member: Ernst & Young's global pharmaceuticals & biotechnology steering committee Biotechnology Industry Research Assistance Council.
Mr. Andy Rayner
Andy Rayner is a graduate Chemical Engineer with 25 years process design experience, principally in the pharmaceutical industry. He has been PM Dublin's leading pharma specialist for the past 20 years and has principally worked on vaccine; cell culture and fill finish projects in the last ten years.
Mr. Venkat Jasti
Mr.Venkat Jasti is a Post Graduate in Pharmacy from Andhra University, Visakhapatnam, and also a Post Graduate in Pharmacy from St. John University, New York, specializing in Industrial Pharmacy. Having registered himself as a Registered Pharmacist, he successfully owned and operated a chain (6) of community pharmacies in the state of NY and NJ from 1977 till 1989.
Dr. Nata Menabde
Dr Nata Menabde is WHO Representative to India. She has a solid public health academic background and 28 years of experience as a health professional, during which she has built an extensive track record in public health and health systems at country and international levels. As a leader, she has proven her ability to instil a clear vision, effective teamwork and high performance in the organizations she has led.
Dr. Shreemanta K Parida
Dr. Shreemanta K Parida is an infectious disease clinician from India with PhD in Immunology from National Institute of Immunology. His journey to be a globally recognised clinician scientist spans over a quarter century with extensive training in the field of molecular immunology, vaccinology, infectious diseases, molecular pathogenesis, epidemiology and clinical trials in many centres of excellence in Europe (WHO-Immunology Research Training Centre in Geneva,
Dr. Sanuj Ravindran
Dr. Sanuj Ravindran is the Managing Director of Asian Healthcare Fund, a New Delhi based PE fund that is exclusively focused on healthcare and life sciences in India. Previously, as a Principal of Radius Ventures, Dr. Ravindran invested in and assumed Board roles with Ambit Biosciences, Athersys Inc and Resolvyx Pharmaceuticals, and worked closely with Biostorage Inc.